ACR Appropriateness Criteria® Resectable Stomach Cancer

Parima Daroui, Salma K. Jabbour, Joseph M. Herman, May Abdel-Wahab, Nilofer Azad, A. William Blackstock, Prajnan Das, Karyn A. Goodman, Theodore S. Hong, William E. Jones, Harmeet Kaur, Andre A. Konski, Albert C. Koong, Rachit Kumar, Timothy M. Pawlik, William Small, Charles R. Thomas, W. Warren Suh

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


For resectable gastric cancer, perioperative chemotherapy or adjuvant chemoradiation with chemotherapy are standards of care. The decision making for adjuvant therapeutic management can depend on the stage of the cancer, lymph node positivity, and extent of surgical resection. After gastric cancer resection, postoperative chemotherapy combined with chemoradiation should be incorporated in cases of D0 lymph node dissection, positive regional lymph nodes, poor clinical response to induction chemotherapy, or positive margins. In the setting of a D2 lymph node dissection, especially those with negative regional lymph nodes, adjuvant chemotherapy alone could be considered. The American College of Radiology (ACR) Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review includes an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Original languageEnglish
Pages (from-to)595-602, C3
Issue number8
StatePublished - 1 Aug 2015


Dive into the research topics of 'ACR Appropriateness Criteria® Resectable Stomach Cancer'. Together they form a unique fingerprint.

Cite this